Jaguar Health Reports Crofelemer Use in Infant With GUCY2C-Related Intestinal Failure
Jaguar Health says its family company Napo Pharmaceuticals has provided liquid oral crofelemer to an infant with GUCY2C-related intestinal failure, with reported reductions in parenteral support needs.
Jaguar Health, Inc. (NASDAQ:JAGX) said its family company Napo Pharmaceuticals has continued providing crofelemer powder for oral solution to an infant with intestinal failure caused by a GUCY2C mutation resulting in congenital sodium diarrhea. The company said treatment had been provided for several weeks and was associated with an approximately 15% reduction in the patient’s daily parenteral support needs within the first several weeks.
According to Jaguar, the liquid oral formulation has been well tolerated in the pediatric patient, with no significant clinical or laboratory abnormalities reported. The infant continues to require significant daily parenteral support.
Jaguar described GUCY2C mutation-related congenital sodium diarrhea as the third intestinal failure-related congenital enteropathy being evaluated through expanded access. The other conditions identified by the company are pediatric microvillus inclusion disease (MVID) and short bowel syndrome-related intestinal failure (SBS-IF).
Patients with intestinal failure may be unable to absorb sufficient nutrients, electrolytes and fluids through the digestive system. Jaguar said some patients require lifelong total parenteral nutrition, with or without supplemental intravenous fluids. Together, these treatments make up parenteral support, which may be required for up to seven days per week and up to 20+ hours per day.
The company described parenteral support as supportive and lifesaving, while also stating that it can involve serious, sometimes fatal complications. Jaguar added that children with GUCY2C-related congenital sodium diarrhea face challenges in managing nutritional and electrolyte deficiencies because of the effects on growth and developmental needs.
Jaguar said ongoing investigations of liquid oral crofelemer in pediatric intestinal failure have shown reductions in weekly parenteral support requirements, including when those requirements are normalised to body weight. The company reported no significant clinical or laboratory abnormalities in these investigations.
In one pediatric MVID patient, weekly parenteral support requirements normalised to body weight were reduced by up to 48% following >12 months of liquid oral high-dose crofelemer therapy, according to Jaguar.
Jaguar also reported that, in two pediatric SBS-IF patients, weekly parenteral support requirements normalised to body weight were reduced up to 40% following >12 months of liquid oral high-dose crofelemer therapy.
Jaguar said it plans to file a New Drug Application for crofelemer in MVID in mid-2027 to seek approval from the U.S. Food and Drug Administration. The company said the proposed application would include data from an ongoing pivotal trial, which has completed enrollment.
Napo is continuing its global development programme for oral crofelemer as adjunctive therapy to parenteral support in pediatric rare intestinal failure diseases, according to Jaguar.
Jaguar describes crofelemer as an oral plant-based prescription medicine purified from the red bark sap of the Croton lechleri tree, also known as “dragon’s blood,” in the Amazon Rainforest. The company said Napo has established a harvesting programme under fair trade practices for the medicine.
Jaguar Health is a commercial-stage pharmaceuticals company developing prescription medicines derived from plants from rainforest areas for gastrointestinal distress in people and animals. Its family companies Napo Pharmaceuticals and Napo Therapeutics focus on crofelemer powder for oral solution for rare and orphan gastrointestinal disorders involving intestinal failure, including MVID and SBS.
Jaguar Health said Napo Pharmaceuticals has provided liquid oral crofelemer to an infant with GUCY2C-related congenital sodium diarrhea and intestinal failure.
The company reported an approximately 15% reduction in the patient’s daily parenteral support needs within the first several weeks.
Jaguar said GUCY2C-related congenital sodium diarrhea is the third intestinal failure-related congenital enteropathy being evaluated under expanded access.
The company plans to file an NDA for crofelemer in MVID in mid-2027, based on data that will include results from a pivotal trial that has completed enrollment.
Jaguar Health announced that its family company Napo Pharmaceuticals has continued providing crofelemer powder for oral solution for several weeks to an infant with intestinal failure caused by a GUCY2C mutation resulting in congenital sodium diarrhoea. The therapy was reported as well tolerated and associated with reduced daily and weekly parenteral support needs, with no significant clinical or laboratory abnormalities.
Jaguar Health made the announcement on October 21, 2026. It covered several weeks of treatment with liquid oral crofelemer in an infant patient with intestinal failure caused by congenital sodium diarrhoea due to a GUCY2C mutation.
Jaguar Health reported that the patient’s daily parenteral support needs had been reduced by approximately 15% within the first several weeks of liquid oral crofelemer therapy. The patient still requires significant daily parenteral support, according to the company.
Jaguar Health said GUCY2C mutation-related congenital sodium diarrhoea is the third intestinal-failure-related congenital enteropathy being evaluated under expanded access, alongside microvillus inclusion disease and short bowel syndrome. The company said crofelemer has demonstrated benefit in reducing weekly parenteral support needs in paediatric patients with microvillus inclusion disease and short bowel syndrome.
Jaguar Health said it plans to file a New Drug Application for crofelemer for microvillus inclusion disease in mid-2027 to obtain FDA approval. The company said the application is expected to be based on data that will include results from an ongoing pivotal trial, which has completed enrolment.
Jaguar Health said patients with intestinal failure may require lifelong total parenteral nutrition, with or without supplemental intravenous fluids, together comprising parenteral support for up to seven days per week and up to 20+ hours per day. The company described parenteral support as supportive and lifesaving but associated with serious, sometimes fatal complications.
Jaguar Health said paediatric congenital sodium diarrhoea patients with a GUCY2C mutation face a significant challenge in managing nutritional and electrolyte deficiencies because of the higher impact on growth and developmental needs. The company said the reported patient requires significant daily parenteral support.
Jaguar Health said one paediatric microvillus inclusion disease patient had weekly parenteral support requirements normalised to body weight reduced by up to 48% following >12 months of liquid oral high-dose crofelemer therapy. The company reported no significant clinical or laboratory abnormalities in the ongoing investigations.
Jaguar Health said two paediatric short bowel syndrome patients had weekly parenteral support requirements normalised to body weight reduced up to 40% following >12 months of liquid oral high-dose crofelemer therapy. The company reported no significant clinical or laboratory abnormalities in the ongoing investigations.
Jaguar Health describes crofelemer as a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as “dragon’s blood”, of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting programme under fair trade practices for the medicine, according to the company.
Jaguar Health is a commercial-stage pharmaceuticals company focused on developing proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Its family companies Napo Pharmaceuticals and Napo Therapeutics focus on developing and commercialising crofelemer powder for oral solution for rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
Jaguar Health is identified in the announcement as trading on NASDAQ under the ticker symbol JAGX. The source gives the listing as “NASDAQ:JAGX”.